A 42-year-old woman from Delhi presents with a 6-month history of symmetrical pain and swelling of the small joints of both hands, wrists, and feet. Morning stiffness lasts 2 hours. On examination, she has soft tissue swelling over the PIP and MCP joints bilaterally, with reduced grip strength. Laboratory investigations show: ESR 68 mm/h, CRP 12 mg/dL, RF 1:320 (positive), anti-CCP antibodies 85 U/mL (positive). X-ray hands shows periarticular osteopenia and early marginal erosions at MCP joints. She has no other systemic manifestations. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** This patient has established RA (seropositive, erosive, polyarticular) with poor prognostic indicators (high RF, positive anti-CCP, radiographic erosions, prolonged morning stiffness). Early aggressive DMARD therapy is the standard of care. ## Rationale for Correct Answer **High-Yield:** Methotrexate monotherapy at 15 mg weekly is the first-line DMARD for RA in most guidelines, including ACR 2021 and EULAR 2019. It is: - Most effective single agent for RA - Best evidence base for efficacy and safety - Rapid onset (6–8 weeks) - Allows dose escalation up to 25 mg/week if needed - Cost-effective and widely available in India **Clinical Pearl:** Early initiation of DMARDs (within 3 months of symptom onset) significantly improves long-term outcomes and prevents irreversible joint damage. This patient has erosions already, making delay inadvisable. ## Why This Patient Needs DMARDs Now | Feature | Significance | |---------|-------------| | Symmetrical polyarticular involvement | Typical RA pattern | | Morning stiffness >1 hour | Inflammatory arthritis | | High RF and anti-CCP | Seropositive, aggressive disease | | Radiographic erosions | Structural damage already present | | ESR/CRP elevation | Active inflammation | **Mnemonic: DMARD Initiation Triggers — "SERF"** - **S**ymmetrical polyarticular swelling - **E**rosions on imaging - **R**F/anti-CCP positive - **F**unctional impairment (reduced grip strength) ## Pre-DMARD Baseline Investigations Before starting methotrexate, ensure: - Complete blood count (baseline WBC, platelets) - Liver function tests (AST/ALT, albumin) - Renal function (creatinine, eGFR) - Hepatitis B and C serology - Tuberculosis screening (Mantoux or IGRA) **Warning:** Do NOT delay DMARD initiation pending these tests if already done — proceed with methotrexate if baseline labs are normal. ## Monitoring During Methotrexate Therapy 1. FBC, LFT every 8–12 weeks initially, then every 12 weeks 2. Clinical assessment at 6–8 weeks for response 3. If inadequate response at 12 weeks, escalate dose or add second DMARD 4. Folic acid 5 mg daily (on non-methotrexate days) to reduce toxicity [cite:Harrison 21e Ch 313]